The following content is sponsored by Americans for Limited Government.

At a White House press conference last month, President Donald Trump announced a breakthrough on lower drug prices and promised he would take action against European countries who haven’t been paying their fair share for the medicines Americans innovate and invent.

“That’s why my administration is also taking historic action to investigate the unfair and discriminatory trade practices of other countries that extort our pharmaceutical makers to shift costs onto the American consumer,” Trump said.

The Financial Times is now reporting that action is coming soon:

The imminent investigation, which would come under Section 301 of the Trade Act of 1974, would consider whether any US trading partners are underpaying for

See Full Page